Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 4Completed 3Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 129Breast Neoplasms 113Neoplasms 97Neoplasm Metastasis 78Melanoma 73Leukemia, Myeloid, Acute 69Colorectal Neoplasms 69Prostatic Neoplasms 60Multiple Myeloma 52Lung Neoplasms 52Ovarian Neoplasms 51Squamous Cell Carcinoma of Head and Neck 46Triple Negative Breast Neoplasms 42Recurrence 41Carcinoma, Renal Cell 39Carcinoma, Hepatocellular 39Pancreatic Neoplasms 36Myelodysplastic Syndromes 36Glioblastoma 35Brain Neoplasms 34Lymphoma 31Stomach Neoplasms 30Lymphoma, Non-Hodgkin 30Endometrial Neoplasms 30Leukemia 29Lymphoma, Large B-Cell, Diffuse 28Head and Neck Neoplasms 28Uterine Cervical Neoplasms 26Cholangiocarcinoma 26Urinary Bladder Neoplasms 24

Interventions

tislelizumab 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Metastatic Solid Tumors × 1 year × Clear all
NCT06585488 2026-06-03

A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

BeOne Medicines

Phase 1 Terminated
47 enrolled
GastrointestinalOther solid neoplasmThoracic

Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡